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Pediatric Renal Transplantation Under FK 506 Immunosuppression 
C.W.B. Jensen. M.L Jordan. F.X. Schneck. R. Shapiro. A. Tzakis. T.R. Hakala, and T.E. Starzl 
RENAL transplantation (I: cadaveric and 4 living-
related donors' was performed in 16 pediatric recip-
ients (mean age 10.8 yean) under FK 506 immunosuppres-
sion in combination with prednisone therapy. At a mean 
foUow-up of 8.5 months. patient and graft survival rates 
are 100% and 94%. respectively. The only graft loss was 
due to recurrent hemolytic uremic syndrome (HUS) 4 days 
after transplantation. In the functioning grafts. the mean 
serum creatinine is 1.29 :t 0.38 mgldL and the mean BUN 
is 26.0 :: 9.6 mgldL. Seven pa.tients are taking no pred-
nisone. five are receIving 2.5 to 5 mg per day, and three are 
taking 10 to 15 mg per day. 
There were a total of nine rejection episodes in six 
patients and these were all successfuUy reversed. Compli-
cations of transplantation included one patient each with 
cytomegalovirus (CMV). pyelonephritis. a seizure disor-
der and headaches: two patients each developed insulin-
dependent diabetes mellitus. and a posttransplant lym-
phoma WTLD). These results would suggest that FK 506 
is a potent immunosuppressant when used in the pediatric 
age group. The use of FK 506 for the immunosuppression 
of pediatric renal transplant recipients would appear to 
have the advantage of allowing for steroid withdrawal in a 
significant number of patients. thereby minimizing the 
steroid-related complications of which the pediatric popu-
lation is at particular risk. 
MATERIALS AND METHODS 
Sixteen renal transplants ( 12 cadaveric and 4 living related) were 
performed In 16 pedlatnc pauents 17 females and 9 males. mean 
age 10.8 : 3.7 yean: range 3.3 to 16.2 yean' between December 
14. 1989. and July 9. 1991. Twelve of these cases were primary 
transplantations and four were retransplants. Follow-up in these 
pallenls ranged from 0.6 to IS.2 months (mean 8.S months'. All 
pauents receIved FK S06 and prednisone as primary Immunosup-
pressIon. 
Two transplants were performed UStng pediatric en· bloc kid-
neys recovered from donors aged 6 months and 3 yean. respec-
tively. Excluding these pediatric donon. the mean donor age was 
21.6 yean c range 4 to 46 yeanl. Mean cold ischellllc lime of the 
kidneys was 33.7 = 6.6 hours (range 24 to 44 hoursl. excluding the 
four living·related donallons. 
Donor and recIpIent HLA·A. HLA·D. HLA·DR Iypinl were 
performed In all cases. but intenllonai donor-reCIpient HLA 
matching was nOI camed OUI. Only one patient had four or more 
anURen matches. Nine of 16 (S6%)transplanls were done with 0-2 
anuRen matches. SIX (38%) had lhree anullCll matches. Ind one 
had I four'lnllgen malch. Multiple mIsmatches were common 
with 12 (75%) havtng three or more antiRens mismatched. Two 
patients were considered to be highly sensitized with panel-
reactive anubodies (PRA) of 97CJf and 1009Ii. respectively. All 
other reClpents had a PRA of less than 109&. AbscMute critena for 
transplantation were ADO compatibility and a negative Iympho-
cytotoxic cross-match usinl current sera. 
The immunosuppressIon consisted of FK S06 in combination 
wilh steroid therapy. FK S06 was started in the recovery room 
with • continuous IV infusion of 0.1 mglkg total daily dose. Oral 
doses staned at O. IS mglkg twice daily with an IV dose overlap of 
121024 hours. SteroId therapy consisted of I g of methylprednis-
olone in the operating room followed by a prednisone taper to 20 
ma per day by postoperative day 6. Funher reductions in pred-
nisone therapy were usually made in decrements of 2.S mg per day 
starting at the third week posttransplant. 
Biopsy-confirmed rejection episodes were treated with one-half 
to I g of IV boluses of methylprednisolone with or without a 
prednisone recycle. Prednisone recycle consIsted of a starting 
dose of 100 to 200 mg I day tapered to 20 mg over 6 days. A S- to 
l!k1ay course of OKTJ. S mg per day IV was insllluted in cases 
of severe or steroid-reSIstant rejection. 
RESULTS 
Patient and Graft Survival and Function 
The clinical characteristics of the 16 patients are summa-
rized in Table I. Patient survival is 100% with a follow-up 
of I to IS months (mean 8.S months). All grafts achieved 
primary function defined as clearance of creatinine in the 
immediate postoperative period with early diuresis. At 
present. 94% of the grafts are functioning. No patient with 
a functioning graft required dialysis from the postoperative 
period onward. The only graft loss occurred in a 4-year-old 
boy with HUS receiving a second transplant with a PRA of 
97%. His first graft was lost 3 years earlier owing to 
recurrent HUS in the graft 10 days after transplantation. 
With this transplant. the patient's allograft had excellent 
initial function until his founn postoperative day when he 
rapidly became anuric. The allograft biopsy demonstrated 
recurrent HUS. and the graft could not be salvaged despite 
thrombolytic therapy. 
The mean serum creatinine (SCR) of the 15 functioning 
grafts is 1.29 :: 0.38 mgldL and mean blood urea nitrogen 
(BUN) is 26.0:: 9.6 mgldL. The mean serum uric acid and 
cholesterol levels are 6.66 !: 1.87 mgldL and 200 :: 54 
mgldL. respectively. 
ImmunosuppreSSIOn 
The daily maintenance doses of FK 506 and prednisone are 
shown in Table I. FK S06 dosage was based on achieving 
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Table 1. CIInIc:8I ChIIl'IICtertstIca of US Pedlatrtc T ... .,..,.nt P ........ Receiving FK 506 
Patient Traneplant Tranaplanl 
No. CaIe No. 
1 12114189 
2 06110190 1 
3 06113190 1 
4 08l26I9O 3 
5 08I30I9O 
6 09I05I9O 1 
7 09119190 1 
8 10110190 2 
9 11I04I90 2 
10 11I09I90 1 






'AI. IaslloIkwHIp (mean 8.5 ITIOIIIIW). 
tPatlenI on ImUfln. 
~ RejIdion 
MIF (y) RejIdion No. 
F 10 no 
F 14 yes 2 
M 15 no 
F 7 yes 2 
M 10 no 
F 14 yes 
M 15 no 
F 12 yes 2 
F 12 yes 
M 9 no 
M 4 no 
M 3 no 
M 8 no 
M 8 no 
M 9 yes 
F 16 no 
12-hour serum trough levels between 1 to 2 ngimL. Aza-
thioprine was not used in combination with FK 506. 
Currently. seven patients (47%) are taking no prednisone. 
five 03%) are taking 5 mg or less daily. and three patients 
(20%) are on 10-15 mgld. 
Rejection Episodes 
One or more episodes of rejection occurred in 6 (38%) out 
of 16 grafts. There were a total of nine rejection episodes in 
these six patients. Six (67%) of the rejection episodes 
occurred within the first 30 days after transplantation and 
of these five (56%) occurred within the first 2 weeks. All 
rejection episodes responded to treatment (steroid in 7 
cases. OKT3 in 2) and had a good outcome-that is. a 
decrease in serum creatinine with continued allograft di-
uresis. Seven of the nine rejection episodes were charac-
terized as mild based on allograft biopsy results and a 
minimal rise in serum creatinine. Both episodes requiring 
treatment with OKT3 occurred within 14 days of trans-
plantation in patients with 0% PRA and were successfully 
reversed. 
Complications 
One episode of seizures occurred in a 3-year-old male 
during intravenous induction therapy with FK 506. Sei-
zures in this case were manifested as episodes of unre-
sponsiveness. staring. and lip smacking. The patient was 
treated with phenobarbitol and discontinuation of IV FK 
506. This problem has not recurred While the patient has 
been on oral FK 506 therapy. There were no other neuro-
logic sequelae in this patient. The only other neurologic 
complication was headaches in one patient. which re-
solved when the oral FK 506 was decreased. 
Insulin-dependent diabetes mellitus developed de novo 
PnId-
msone' Faf. 
F1(' IT1!J'd F1(' Iow-up 
OKT3 BUN' Cr" IT1!J'd (nI}'ml) Level (rnontIIs) 
18 0.9 6 2.5 0.7 15.2 
yes 18 1.2 12 0 0.3 13.1 
34 1.7 14 0 0.6 13.1 
yes 26 1.9 6 5 0.3 10.6 
20 0.5 7 0 0.3 9.5 
no 15 1.3 6 2.5 0.4 10.4 
34 1.8 8 0 0.4 9.9 
no 47 2.1 ot 10 0 9.7 
no 42 1.8 8 5 2.6 7.9 
12 1.2 8 2.5 0.4 8.0 
Lost Graft 10 HUS 
34 0.6 6 0 0.6 6.2 
18 1.2 8 0 0.4 6.0 
29 0.8 5 0 0.2 5.3 
no 35 1.2 10 10 1.4 1.6 
20 1.1 12 15 1.5 0.6 
4 months posttransplantation in a 14-year-old patient with 
spina bifida on FK 506 monotherapy. after the treatment of 
a rejection episode with high-dose steroids. This patient 
also developed recurrent allograft pyelonephritis for which 
she has required hospitalization. This may have been 
related to the cause of her end-stage renal disease (ESRD) 
(chronic pyelonephritis with reflux) for which she had 
undergone a sigmoid colocystoplasty with bilateral ure-
teral implantation 6 months prior to transplantation. Six 
months posttransplantation. this patient developed ab-
dominal pain. Radiological investigation and biopsy con-
firmed the presence of a pleomorphic lymphoma (PTLDl. 
One hepatic and two lung lesions have resolved with 
high-dose intravenous acyclovir and cessation of her im-
munosuppression. With resolution of these lesions and the 
development of moderate rejection 2 months later. the 
patient resumed low doses of FK 506 and prednisone while 
receiving oral acyclovir. She currently has excellent graft 
function with a serum creatinine of 1.3 mgldL and no 
evidence radiologically of her PTLD. 
Another patient developed nodular densities in her lungs 
and lymphadenopathy posttransplantation. Although the 
investigations and biopsies failed to disclose the etiology of 
these lesions. a presumptive diagnosis ofPTLD was made. 
After the cessation of FK 506 and prednisone and with the 
administration of intravenous acyclovir. there was com-
plete resolution of these lesions. Currently. the patient is 
being maintained on oral acyclovir. FK 506. and pred-
nisone. with stable graft function. 
The only other episode of infection was CMV in a 
12-year-old girl who presented 2 months after transplanta-
tion with fever and an increase in serum creatinine. CMV 
was diagnosed on a culture of the serum buffy coat and 
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was treated successfullv with a IO-day course of ganciclo-
vir. 
DISCUSSION 
Renal transplantation is the treatment of choice for many 
children with end·stage renal disease because of improve-
ments in immunosuppressive drug regimens. Since these 
regimens rely on combination cyclosporine-prednisone 
therapy. they carry with them inherent steroid-related 
complications including cataracts. obesity. Cushing's syn-
drome. diabetes. infection. growth retardation. and avas-
cular bone necrosis. Several studies in the pediatric pop-
ulation have demonstrated the efficacy of limiting steroid 
use in an effort to avoid steroid complications. panicularly 
allowing improvement in catch-up growthKD·~ The toxic 
effects of cyclosporine tCyA) in children are significant 
and include hirsutism (100%). hypertension 1739(). fine 
tremor (34%). acute reversible nephrotoxicity (10%1. and 
hyperuricemia with long·term CyA usage.1.J 
FK 506. a product of the fungus SlreplOmVCf'S 151111./1-
haensis. has a chemical structure and cytosolic binding 
sites different from C\:\.-I-7 Despite being 100 times more 
potent than CyA in vitro. FK 506 does share the neuro-
toxicity. nephrotoxicity. and diabetogenicity of Cy A. 4.3 
The neurotoxicity observed with the intravenous formula-
tion (tremors. headaches. insomnia. parathesias. and a 
sensation of racing) is diminished with oral therapy. in 
which only 13% of patients report symptoms.s 
In this study. 137r of patients developed neurotoxicity 
(seizures and headaches) and two patients had minor 
infections (recurrent pyelonephritis and CM V syndrome I. 
The drug's potency has allowed for the discontinuation of. 
or a significant reduction in. prednisone therapy in 807r of 
the patients in this study. Additionally. hirsutism and 
gingival hvperplasia have not been noted in this study 
group and hyperuricemia was seen in only 53% of our 
patients. On the other hand. the development of one 
proven PTLD and one presumed PTLD and the develop-
ment of insulin-dependent diabetes meUitus in two patients 
30n 
are significant deterrents to the usage of FK 506. despite 
the reversal of the two cases of PTLD and the discontin-
uation of insulin therapy with the termination of pred-
nisone in the two patients with diabetes. 
Our patient and graft survival rates of lOOo/C and 947f. 
respectively. with a mean follow-up of 8.5 months. are 
encouraging. Significantly. the incidence of acute rejection 
was low 138%1. early (679( occurred within the first month 
after transplantation). and mild 178%). All rejection epi-
sodes were reversed. including the two severe rejection 
episodes requiring OKT3 treatment. Nevertheless. 80% of 
our patients were on no prednisone 17 patients) or low 
dosages (5 patients: ~KR-R mgld) of prednisone. results 
noted in the adult population.'I Therefore. it would appear 
that FK 506 is an effective form of immunosuppression in 
the pediatric renal transplant population. It appears to 
have the significant advantages of avoiding high-dose 
prednisone therapy and the specific CyA-related compli-
cations. which are both bothersome in the pediatric pop-
ulation. The development of one and possibly two post-
transplant lymphomas. both reversed. is a concern that 
will need to be addressed. perhaps by dose reduction in 
certain patients. 
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